CytoMed Therapeutics (GDTC) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed CytoMed Therapeutics (GDTC) over the past year, gaining 451.9% versus a loss of 56.5%. GT Biopharma is the larger company by market cap ($12.1 million vs $10.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | GTBP |
|---|---|---|
| Share price | $0.89 | $6.68 |
| Market cap | $10.62M | $12.05M |
| 1-day change | -5.81% | +12.27% |
| YTD return | -29.22% | +659.24% |
| 1-year return | -56.46% | +451.85% |
| 5-year return | — | -96.72% |
| EPS (TTM) | $-0.23 | $-147.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.68 | $28.75 |
| 52-week low | $0.68 | $4.91 |
| Distance from 52-week high | -75.82% | -76.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +367.42% | +1022.75% |
| Average volume | 78.66K | 55.52K |
| Shares outstanding | 11.93M | 1.80M |
| Employees | 42 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed GDTC by 508.3 percentage points over the past year.
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
GDTC vs GTBP FAQ
Which is bigger, CytoMed Therapeutics or GT Biopharma?
GT Biopharma (GTBP) is larger, with a market capitalization of $12.05M compared with $10.62M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, GDTC or GTBP?
GTBP returned +451.85% over the past 12 months, compared with -56.46% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.